File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.22608/APO.201870
- Scopus: eid_2-s2.0-85049227279
- PMID: 29737052
- WOS: WOS:000453997500007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Retinoblastoma for Pediatric Ophthalmologists
Title | Retinoblastoma for Pediatric Ophthalmologists |
---|---|
Authors | |
Keywords | RB1 mutation TNMH classification retinoblastoma |
Issue Date | 2018 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://journals.lww.com/apjoo/pages/default.aspx |
Citation | Asia Pacific Journal of Ophthalmology, 2018, v. 7 n. 3, p. 160-168 How to Cite? |
Abstract | Retinoblastoma can present in 1 or both eyes and is the most common intraocular malignancy in childhood. It is typically initiated by biallelic mutation of the RB1 tumor suppressor gene, leading to malignant transformation of primitive retinal cells. The most common presentation is leukocoria, followed by strabismus. Heritable retinoblastoma accounts for 45% of all cases, with 80% being bilateral. Treatment and prognosis of retinoblastoma is dictated by the disease stage at initial presentation. The 8th Edition American Joint Committee on Cancer (AJCC) TNMH (tumor, node, metastasis, heritable trait) staging system defines evidence-based clinical and pathological staging for overall prognosis for eye(s) and child. Multiple treatment options are available in 2018 for retinoblastoma management with a multidisciplinary team, including pediatric ocular oncology, medical oncology, radiation oncology, genetics, nursing, and social work. Survival exceeds 95% when disease is diagnosed early and treated in centers specializing in retinoblastoma. However, survival rates are less than 50% with extraocular tumor dissemination. We summarize the epidemiology, genetics, prenatal screening, diagnosis, classification, investigations, and current therapeutic options in the management of retinoblastoma. |
Description | Link to Free access |
Persistent Identifier | http://hdl.handle.net/10722/277426 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.545 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | AlAli, A | - |
dc.contributor.author | Kletke, S | - |
dc.contributor.author | Gallie, B | - |
dc.contributor.author | Lam, WC | - |
dc.date.accessioned | 2019-09-20T08:50:51Z | - |
dc.date.available | 2019-09-20T08:50:51Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Asia Pacific Journal of Ophthalmology, 2018, v. 7 n. 3, p. 160-168 | - |
dc.identifier.issn | 2162-0989 | - |
dc.identifier.uri | http://hdl.handle.net/10722/277426 | - |
dc.description | Link to Free access | - |
dc.description.abstract | Retinoblastoma can present in 1 or both eyes and is the most common intraocular malignancy in childhood. It is typically initiated by biallelic mutation of the RB1 tumor suppressor gene, leading to malignant transformation of primitive retinal cells. The most common presentation is leukocoria, followed by strabismus. Heritable retinoblastoma accounts for 45% of all cases, with 80% being bilateral. Treatment and prognosis of retinoblastoma is dictated by the disease stage at initial presentation. The 8th Edition American Joint Committee on Cancer (AJCC) TNMH (tumor, node, metastasis, heritable trait) staging system defines evidence-based clinical and pathological staging for overall prognosis for eye(s) and child. Multiple treatment options are available in 2018 for retinoblastoma management with a multidisciplinary team, including pediatric ocular oncology, medical oncology, radiation oncology, genetics, nursing, and social work. Survival exceeds 95% when disease is diagnosed early and treated in centers specializing in retinoblastoma. However, survival rates are less than 50% with extraocular tumor dissemination. We summarize the epidemiology, genetics, prenatal screening, diagnosis, classification, investigations, and current therapeutic options in the management of retinoblastoma. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://journals.lww.com/apjoo/pages/default.aspx | - |
dc.relation.ispartof | Asia Pacific Journal of Ophthalmology | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.subject | RB1 mutation | - |
dc.subject | TNMH classification | - |
dc.subject | retinoblastoma | - |
dc.title | Retinoblastoma for Pediatric Ophthalmologists | - |
dc.type | Article | - |
dc.identifier.email | Lam, WC: waichlam@hku.hk | - |
dc.identifier.authority | Lam, WC=rp02162 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.22608/APO.201870 | - |
dc.identifier.pmid | 29737052 | - |
dc.identifier.scopus | eid_2-s2.0-85049227279 | - |
dc.identifier.hkuros | 305714 | - |
dc.identifier.volume | 7 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 160 | - |
dc.identifier.epage | 168 | - |
dc.identifier.isi | WOS:000453997500007 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 2162-0989 | - |